Flavanone aglycone; as naringin glycoside from grapefruit it is a well-characterised CYP3A4 and OATP1A2/2B1 inhibitor — the 'grapefruit juice effect' on statin and CCB pharmacokinetics. Activates PPARα (lipid oxidation) and inhibits ApoB secretion; LDL reduction in animal models.
Half-Life (t½)
PO: 2.31h
Dosing Guidelines
PO: Typical 83.3 mg (Range: 50–150 mg)
Target Organ Systems
cardiovascular
digestive
Interactions
Hesperidin (synergistic): Same citrus-flavanone class; complementary in the citrus fruit matrix.
Pathways It Modulates
Nrf2 / Keap1 antioxidant response (activator) — Nrf2 + CYP3A4 modulator (grapefruit constituent — but naringin is the bigger DDI driver)